Analyst Ratings For NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)

Today, HC Wainwright initiated coverage on NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a Buy with a price target of $25.00.

Some recent analyst ratings include

• 5/3/2018-HC Wainwright initiated coverage with a Buy rating.
• 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
• 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
• 4/2/2018-UBS initiated coverage with a Buy rating.
• 4/2/2018-Barclays initiated coverage with a Overweight rating.

Recent Trading Activity for NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
Shares of NASDAQ:BTAI – BioXcel Therapeutics closed the previous trading session at 7.50 up +0.48 6.84% with 7.5 shares trading hands.